Azimut LIFE dac

Solvency and Financial Condition Report

As at December 31, 2020

Executive Summary 5
A. BUSINESS AND PERFORMANCE 9
A.1 Business and external environment 9
A.2 Performance from underwriting activities 10
A.3 Performance from investment activities 11
A.4 Performance of other activities 11
A.5 Any other information 11
B. SYSTEM OF GOVERNANCE 12
B.1 General Information on the System of Governance 12
B.1.1 Overview 12
B.1.1.1 Board of Directors 12
B.1.1.2 Company Secretary 12
B.1.1.3 Committees 12
B.1.2 Main Changes in Governance Structure 17
B.1.3 Remuneration Policy and Practices 17
B.1.4 Material Transactions 18
B.2 'Fit and Proper' Requirements 18
B.3 RISK MANAGEMENT SYSTEM 19
B.4 ORSA 21
B.5 Internal Control System 22
B.6 Internal Audit Function 23
B.7 Compliance Function 23
B.8 Actuarial Function 24
B.9 Outsourcing 24
B.10 Adequacy of the System of Governance 25
C. RISK PROFILE 26
C.1 Underwriting Risk 27
C.2 Market Risk 27
C.3 Credit Risk 28
C.4 Liquidity Risk 28
C.5 Operational Risk 28
C.6 Other Material Risks 29
C.7 Other Information 31
D. VALUATION FOR SOLVENCY PURPOSE 32
D.1 Assets 32
D.1.1 Property, plant and equipment 33

D.1.2 Collective Investment Undertakings and Holdings in related undertakings, including participations 33
D.1.3 Deposit other than cash equivalents 33
D.1.4 Assets held for index-linked and unit-linked contracts 33
D.1.5 Reinsurance recoverables from: Life index-linked and unit-linked 34
D.1.6 Insurance and intermediaries receivables 34
D.1.7 Receivables (trade, not insurance) 34
D.1.8 Cash and cash equivalents 34
D.2 Technical Provision 34
D.3 Other Liabilities 35
D.3.1 Deferred Tax Liabilities 35
D.3.2 Insurance & intermediaries payables 36
D.3.3 Reinsurance payables 36
D.3.4 Payables (trade, not insurance) 36
D.3.5 Others 36
D.4 Alternative methods of valuation 36
D.5 Any other information 36
E. CAPITAL MANAGEMENT 38
E.1 Own Funds 38
E.1.1 Objectives, policies and processes employed for managing own funds 38
E.1.2 Analysis and details of own funds items 38
E.1.3 Material differences between equity as shown in Azimut Life's financial statements and the excess of assets over liabilities as calculated for solvency purposes 39
E.1.4 Basic own funds subject to transitional arrangements 39
E.1.5 Ancillary own funds 39
E.1.6 Items deducted from own funds 39
E.1.7 Own funds 39
E.2 Solvency Capital Requirement and Minimum Capital Requirement 40
E.2.1 SCR and MCR – Comparison with previous year end 40
E.2.2 SCR Split by risk module 40
E.2.3 Standard Formula Simplification 40
E.2.4 Specific parameters of the Standard Formula 40
E.2.5 Capital Add-ons 40
E.2.6 MCR Input 40
E.3 Use of the duration-based equity risk sub-module in the calculation of the Solvency Capital Requirement 41
E.4 Internal Model Information 41

E.5 Non-compliance with the Minimum Capital Requirement and non-compliance with the Solvency Capital Requirement 41

E.6 Any other information 41

APPENDIX 1 – REPORTING TEMPLATES 42

APPENDIX 2: ANNUAL QUANTITATIVE REPORTING TEMPLATES 43

Executive Summary

The content of this document is prescribed by the regulation and contains the following sections: Business and Performance, System of Governance, Risk Profile, Valuation for Solvency Purposes and Capital Management. The responsibility of public disclosure is ultimately held by the Board of Directors (the "Board") supported by other functions in the Company (such as Finance, Risk, Compliance and Actuarial Functions) in order monitor and manage the business.

The Company's business model as a life assurance Company is to establish and manage unit-linked policies which are sold cross-border into the Italian market, under the freedom of establishment regime. The Company has a distribution agreement in place with one single distributor, Azimut Financial Insurance, which is a company of the Azimut Group.

Effective on 31st July 2020, the Company changed its name to Azimut Life dac.

In relation to the overall business, the global Covid-19 pandemic has had an impact on the market value of the linked assets during the year, as well as a temporary reduction in sales. Nevertheless, by the end of the year the market values of the linked assets have recovered and surpassed their pre Covid-19 levels and the net collection has overall been positive, particularly due to the reduction in surrender claims. The growth recorded in 2020 was also driven by the internal funds performance. Despite the events which occurred in 2020, the underlying risk profile of the Company remained substantially unchanged. The product offering of the Company was reviewed and updated, effective from August 2020: three additional non-compulsory death benefits were made available for all the products of the Company (AZ Galaxy, AZ Navigator and AZ Infinity Life); the list of internal funds was updated (9 mergers and 5 new established internal funds); AZ Galaxy and AZ Navigator policyholders could have access to the same list of internal funds. The Own Funds and the Solvency Capital Requirement ("SCR") of the Company increased, while the Solvency Ratio slightly reduced at year end. The Solvency II ratio decreased from 206% at 31st December 2019 to 199% at 31st December 2020. The amount of SCR as of the end of 2020 was equal to €168.9 million and the amount of eligible own funds to cover the SCR was equal to € 336.4 million, consisting of all Tier 1 assets: €0.65 million as Ordinary Share Capital, €9.35 million as capital contribution, approved by the Central Bank of Ireland as own fund Tier 1 and € 326.4 million as reconciliation reserve. The Own Funds are reported net of the amount of € 55.9 million of foreseeable dividends the Company intends to pay in 2021 in relation to its 2020 result. The same own funds are eligible to meet MCR, which amounts to € 42.2 million.

The Company is mainly exposed to the following risks, further commented in section C:

- Higher lapses than expected, leading to a reduction in both immediate income and the capitalised value of the projected future income stream;
- Fall in Assets Under Management potentially due to adverse market impact, reducing both immediate income and the capitalised value of the projected future income stream;
- Higher expenses than expected, reducing the profitability of the Company.

Even though those risks may impact on the Company's profitability and the capacity to pay dividends to the shareholder, they are not expected to impact on the Company's ability to meet the obligations towards the policyholders.

Azimut Life focuses on increasing income by increasing the net assets under management. This is achieved by generating new business whilst reducing lapses.

It should be noted that whilst a fall on the Assets Under Management would reduce both immediate income and the capitalised value of the projected future income stream, it would also reduce some of the expenses and the associated SCR, so would not have a significant impact on the Solvency II Solvency Ratio.

The below table reports the main indicators for the underwriting performance of the Company.

€/000	31/12/2020	31/12/2019	2020 vs 2019
Premiums Earned	665,514	678,649	-2%
of which classified as insurance premiums under IFRS	*5,351*	*9,608*	-44%
Claims and benefit incurred	619,773	804,947	-23%
Of which classified as claims within FS	*144,492*	*160,870*	-10%
Unit Linked Fund at the beginning of the year	6,077,837	5,682,438	+7%
Unit Linked Fund at the end of the year	6,178,133	6,077,837	-2%

Detailed below is the composition of premium earned by product:

€/000	2020
Galaxy	533,283
AZ Infinity Life	87,322
AZ Navigator & Plus	44,909
Total	**665,514**

As mentioned above, the distribution into the Italian market is carried by a single distributor, hence all the premium refers to its activity.

The Company is required to hold sufficient assets to match the policyholders liabilities at all times and the Board has the primary responsibility to ensure the Company has the adequate level of capital to cover its solvency needs, in relation to the nature and scale of the business, and to fulfil any liquidity obligation in the short to medium term.

The Company's financial year end is 31st December each year and it reports its results in Euro.

Following the review performed by the Central Bank of Ireland ("CBI") and as per the letter received on 5th June 2020, the Company is now classified as a Medium Low Risk firm under the CBI's risk-based framework for the supervision of regulated firms, known as PRISM or Probability Risk and Impact System. The Company is subject, in relation to its governance, to the provisions of the Companies Act of 2014 and the CBI's Corporate Governance Requirements for Insurance Undertakings of 2015.

The Board and Relevant Officers have primary responsibility for ensuring that the Company is suitably managed and directed. Accordingly, it is of paramount importance that the Directors and Relevant Officers of Azimut Life have integrity and are suitable, as these individuals can have significant and direct impact on the safety, soundness and reputation of the Company and the Azimut Group (the "Group") of which the Company is part.

The Company has established a 'Fit and Proper' policy to ensure that existing and new Directors and Relevant Officers of the Company are fit and proper: appropriate for the position to which they may be appointed and continue to be fit and proper while they hold their position.

The Board of Directors of the Company retain ultimate responsibility for the oversight of the business and the definition of the Company's general strategies and risk appetite. The implementation of the strategy is mandated to the CEO in Dublin.

As of 31.12.2020, the Board had established five committees, among which Products and Investment operate as executive committees:

- Audit Committee;
- Risk and Compliance Committee;
- Remuneration Committee;
- Products Committee;
- Investment Committee.

In addition to the committees, a periodical Senior Management Governance Forum ("SMGF") operates, as the venue and occasion for sharing information and for discussing aspects, including relevant issues across the 3 lines of defence.

Significant events – COVID-19

As at April 2021, the worldwide outbreak of the Covid-19 coronavirus is still a significant event. The Company recovered from the short-term reduction of assets under management, experienced during the first wave of Covid-19 mostly as a result of the financial markets volatility. As of the end of 2020, the Assets Under Management were about €6.2bln, overall increasing from the beginning of the year by almost 2%.

The Company has, overall, experienced in 2020 a non-material impact on death claims as a result of Covid-19. The impacts of Covid-19 on mortality risks are expected to remain non material, since the Company has a limited exposure to mortality risk as the level of death benefit offered is a relatively low portion of the overall value of all policies and a significant part of the risk is ceded to a primary reinsurer.

There were no issues in relation to the Solvency Ratio and liquidity position during 2020 as a result of the Covid-19 outbreak.

At the start of the Covid-19 outbreak, the Company successfully activated the Business Continuity Plan aimed at protecting employees' health and safety, with almost all employees working remotely during the breakout. The business activities did not experience any operational slowdown as a result of most employees working remotely and with all the key service providers, including the policy administrator and fund administrator, operating efficiently whilst working remotely too.

A. BUSINESS AND PERFORMANCE

A.1 Business and external environment

Azimut Life dac is a regulated unit-linked life assurance private company limited by shares. The Company's registered office is: 1st Floor, Block 5, Irish Life Centre, Abbey Street Lower, Dublin, D01 P767, Ireland.

The responsibility for the financial supervision of the Company lies with the Central Bank of Ireland ("CBI"), whose address is: PO Box 559, New Wapping Street, North Wall Quay, Dublin 1, Ireland.

The Company's external auditor is PricewaterhouseCoopers, Chartered Accountants and Statutory Audit Firm, One Spencer Dock, North Wall Quay, Dublin 1, Ireland.

The Company is wholly owned by Azimut Holding S.p.A. ("Azimut Holding"), an Italian holding company, listed on the Milan Stock Exchange and ranked amongst the top 40 companies of the index. The Azimut Group is the largest independent asset management Group in Italy since 1989 with a presence in more than 15 countries all over the world.

The Company is authorized to carry on Class I and III business under the Solvency II Directive, however, currently all policies issued by the Company are classified as "Life insurance obligations – Index-linked and unit-linked insurance" (line of business D(31) as per the SII Directive), through cross-border activity into the Italian market. The Company relies on third parties' services for, among others, policy administration and internal fund administration activities.

No significant events were noted outside those outlined above in Section "Significant events – COVID19".

The shareholder, Azimut Holding, has the entire stake in the Company and 100% of the voting rights as presented in the organisational chart below.



Source: Company data as at 31/12/2020. Note (1): Controls distribution companies M&O Consultoria, FuturaInvest and Azimut Brasil Wealth Management. Note (2): controls AZ Sinopro Insurance Planning. Note (3): Controls 100% of CGM Italia SGR. Note (4): 30% is owned by Azimut Capital Management and 19% by Azimut Financial Insurance, both fully owned by Azimut Holding. Formerly AZ Fund. Note (5): controls SDB Financial Solutions. Note (6): Closed in Feb. 2021.

A.2 Performance from underwriting activities

The Company's portfolio was issued in Italy to Italian resident policyholders and only in a few cases to clients having fiscal residence outside Italy.

As the business traded by the Company is related to unit-linked insurance policies, the underwriting risk is very limited.

The overall amount of premiums is reported within the audited Financial Statements of the Company, prepared in accordance with the International Financial Reporting Standards (IFRS), based on the following rules: for investment contracts, premiums and claims are not reflected in the statement of comprehensive income as written premiums, claims and benefit incurred, but rather are reflected in the Statement of Financial Position in the financial assets and liabilities in accordance with IAS 39; insurance contracts, premiums and claims are disclosed separately within the Financial Statements.

As the Company markets its products within the Italian market with one line of business only (Unit Linked policies), the following figures are related to the entire Company.

€/000	**31/12/2020**	**31/12/2019**	**2020 vs 2019**
Premiums Earned	665,514	678,649	-2%
of which classified as insurance premiums under IFRS	*5,351*	*9,608*	-44%
Claims and benefit incurred	619,773	804,947	-23%
Of which classified as claims within FS	*144,492*	*160,870*	-10%
Unit Linked Fund at the beginning of the year	6,077,837	5,682,438	+7%
Unit Linked Fund at the end of the year	6,178,133	6,077,837	+2%

The amount of premiums earned in 2020 is in line with the level of the previous year. Such trend is consistent with the market and the overall performance of the Company's distributor.

Claims incurred decreased substantially compared to 2019.

The resulting net collection was positive by € 45,741k and the total Assets Under Management (AUM) increased also due to the performance of the internal funds.

A.3 Performance from investment activities

In consideration of the nature of the products sold by the Company, no investment risk is taken by the Company on behalf of policyholders. The policyholders bear the investment risk in relation to linked assets and the Company's role is to manage policyholders assets in accordance with the investment policies established for each internal fund. Shareholders' own funds assets are invested in cash, Government Bonds and monetary mutual funds with an aim to have high liquidity and to preserve the capital position of the Company. The returns from such assets are reported as Investment Income within the Statement of Comprehensive Income while the effect deriving from the fair value evaluation at each year end is reported as Other Comprehensive Income and recognised in equity. In 2020 the overall investment income of the Company is not material and turns negative , being equal to about -€5 k (€26 k in 2019).

Azimut Life does not hold any investments in securitisations.

A.4 Performance of other activities

Azimut Life's activity is entirely focused on unit-linked insurance business, as reported in section A.2

The Company's revenues derive from fees and commissions charged on the unit-linked internal funds and on the policies. Once distribution fees are paid, the resulting net amount represents the Company's income.

€/000	**31/12/2020**	**31/12/2019**
Fees earned	142,010	114,068
Fees paid	69,064	69,366

The fees earned, and the corresponding amount paid to the distributor, are aligned to last year's result, despite the change in product structure.

€/000	**31/12/2020**	**31/12/2019**
Administration Expenses	7,466	7,981

As far as the administration expenses are concerned, the actual figure for 2020 is lower compared to last year. The reduction is mainly due to the conclusion of some projects and various efficiencies.

A.5 Any other information

No other relevant information to be provided.

B. SYSTEM OF GOVERNANCE

B.1 General Information on the System of Governance

B.1.1 Overview

The Company is now classified as a Medium Low Risk firm under the CBI's risk-based framework for the supervision of regulated firms, known as PRISM or Probability Risk and Impact System. The Company is subject, in relation to its governance, to the provisions of the Companies Act of 2014 and the CBI's Corporate Governance Requirements for Insurance Undertakings of 2015.

The Board of Directors of the Company retains ultimate responsibility for the oversight of the business and the definition of the Company's general strategies and risk appetite. The implementation of the strategy is mandated to the executive management in Dublin.

B.1.1.1 Board of Directors

As of 31.12.2020, the Board of the Company was comprised of eight directors, among whom three executive (PCF 1) and five non-executive (PCF 2), including two Independent Non-Executive Directors ("INED's"). Meetings are validly held and resolutions passed with a majority of the members of the Board.

The Board of Azimut Life, as of 31.12.2020, was so composed:

1. Marita Freddi – Chairperson (PCF 2 and PCF 3)
2. Filippo Fontana – General Manager (PCF 1 and PCF 8)
3. Giacomo Mandarino – (PCF 1)
4. Giuliana Barocelli – (PCF 1)
5. Paul Dalton - Chair of Audit Committee (INED, PCF 2 and PCF 4)
6. Clive Kelly - Chair of Risk and Compliance Committee (INED, PCF 2 and PCF 5)
7. Claudio Basso - (PCF 2)
8. Joao Gomes Sequeira – (PCF 2)

Ms Giuliana Barocelli was appointed as executive Board Member in April 2020 and approved by the CBI on 14th July 2020.

B.1.1.2 Company Secretary

Matsack Trust Ltd., with registered office in 70 Sir John Rogerson's Quay, Dublin 2, Ireland.

B.1.1.3 Committees

The Company has established the following Committees:

- Audit Committee;
- Risk & Compliance Committee, with two separate sessions covering Risk and Compliance topics respectively;
- Products Committee
- Remuneration Committee; and
- Investment Committee.

The Chairman of the Audit and the Chairman of the Risk & Compliance Committees systematically report to the Board on any matters discussed by the respective Committees, thus ensuring adequate visibility of any relevant issues by all Directors. Furthermore, minutes of the Investment Committee

and Products Committee are presented for noting at each relevant Board meeting, unless a specific decision is required by the respective terms of reference to be resolved at Board level. In such circumstances a dedicated agenda item is arranged within the Board meeting and proper discussion is taken and minuted and the Directors resolve accordingly.

Audit Committee

The Audit Committee is made up of three non-executive directors, the majority of whom are independent, in accordance with the provisions of the 2015 Corporate Governance Requirements for Insurance Undertakings. It resolves with a majority of votes. The Chairman of the Audit Committee is one of the two INEDs of the Company.

The Audit Committee is governed by specific Board approved terms of reference ("TOR") that regulate the functioning and competencies of the Audit Committee, ensuring its independence. For instance, the Audit Committee is granted reasonable and adequate resources to seek expert professional advice where required in order for the Committee to discharge its responsibilities.

The Audit Committee has the following main competencies:

1) Monitors the effectiveness and adequacy of the company's internal control, internal audit and IT systems;
2) Monitors the financial reporting process and submits recommendations and proposals as appropriate;
3) Liaises with the external and internal auditors particularly in relation to their audit findings;
4) Reviews the integrity of the Company's financial statements ensuring that they give a "true and fair view" of the Company's financial status;
5) Reviews any financial announcements and reports and recommends to the Board whether to approve the institution's annual accounts;
6) Assesses the auditors' independence and the effectiveness of the audit process.

The Audit Committee assists therefore the Board in discharging its responsibilities for:

- The integrity and reliability of the Company's financial statements;
- The effectiveness of the Company's audit activities, in the framework of the Company's overall risk management system;
- The monitoring of effectiveness, independence and objectivity of the external auditors and the other subjects involved in the audit functions of the Company.

Risk and Compliance Committee

The Risk and Compliance Committee ("R&CC") is made up of two INEDs, the CRO, an executive director and a non-executive director. The Chairman of the R&CC is one of the two INEDs of the Company.

The R&CC is also governed by specific terms of reference ("TOR") that regulate its functioning and competencies, ensuring its independence.

In relation to Compliance, the R&C Committee has the following main competencies:

1) Reviews the framework established by the Company for monitoring compliance with laws and regulations and the results of management investigations for any non-compliance;
2) Periodically considers the duties and responsibilities of the Compliance Function and evaluates its role in confirming that regulatory and legal obligations are being met;
3) Ensures that a regular compliance update is produced and reviewed by the Head of Compliance of the Company, reporting any material issues, which may for example, negatively affect the Company's reputation, to the Board; and
4) Ensures that reasonable and adequate resources are made available to the function.

In relation to Risk, the R&CC is responsible for the following:

a) Overseeing and providing advice to the Board on the risk exposures of the Company and future risk strategy.
b) Advising the Board on risk appetite and tolerance for future strategy, taking account of the Board's overall risk appetite, the financial position of the Company and, drawing on the work of the Audit Committee, the External Auditor, the Head of Actuarial or any outsourced key service provider and the capacity of the Company to manage and control risks within the agreed strategy.
c) Oversight of the Risk Management Function.
d) Ensuring the development and on-going maintenance of an effective Risk Management System within the Company effective and proportionate to the nature, scale and complexity of the risks inherent in the business.
e) Advising the Board on the effectiveness of strategies and policies with respect to maintaining, on an ongoing basis, amounts, types and distribution of both internal capital and own funds adequate to cover the risks of the institution.

The R&CC assists therefore the Board in:

a) the monitoring and assessment of effectiveness of the Company's Risk Function, in the framework of the Company's overall Risk Management System,
b) the monitoring of effectiveness, independence and objectivity of the Risk and Compliance Function and of any other subject, internal or external (Head of Actuarial, auditors) involved in the assessment of the Risk and Compliance function of the Company, the Company's Risk profile and/or its overall Risk Management System,
c) the implementation of the Company's risk strategy and maintenance thereof, and
d) the oversight of any issues having a potential impact on the risk and/or compliance profile of the Company.

Products Committee

The Products Committee is an executive committee, reporting to the Board, with responsibilities to discuss and analyse any of the following matters:

1. General product offering of the Company, range of products and possible changes, enhancements or improvements;
2. Analysis of characteristics and performances of products, including without limitation, in case of changes, pricing review, in accordance with the applicable Investment Policy of the internal funds;
3. Possible amendments, whether required by changing market or regulatory conditions, or due to requests. Where the amendment is considered material, subject to the prior discussion and approval at the Board. For this purpose:

Material is any amendment that can negatively impact on profit/profitability and/or on the future liquidity or capital position of the Company in a significant manner. For this purpose, significant is an impact that would be considered such by a reasonable person, in a sound and prudent management perspective. The Company will consider material any new products that are not similar by nature and characteristics to existing or previous products (e.g. in terms of profitability, nature of product and applicable rules).

4. Performance benchmarks setting and regular performance review vs. these benchmarks;
5. Product Oversight and Governance (POG) requirements, in line with IDD; and
6. Oversight of the unit pricing operations and reviewing regular reporting over the application of the asset evaluation policy.

The Products Committee is expected to cover the key areas of the new products assessment and oversight, including the identification of the target markets and the process in place to assess the clients are fairly treated, the members being expected to be able to contribute actively to any discussion or assessment based on expertise in any of the following areas:

a. Risk / Actuarial
b. Legal, with regard to the legal / regulatory framework of any involved jurisdiction;
c. Finance and Accounting.
d. Portfolio Management and asset allocation.
e. Marketing and Operations.

In addition, where considered appropriate by the Chairman or any other members, the Committee is authorised to obtain external professional advice and to secure attendance of anyone it considers having the required expertise in specific technical matters related to the creation / monitoring of products or to any of the other matters for which the Committee is competent.

Investment Committee

The Investment Committee is an executive committee, reporting to the Board, with responsibilities to discuss and analyse any of the following matters:

1. Economic scenarios, threats and opportunities of investment.
2. Current and envisaged portfolio allocation, consideration of possible changes.
3. Performance analysis.

The members should be able to contribute actively to any discussion or assessment based on expertise in any of the following areas:

a. Portfolio Management and asset allocation.
b. Economic and financial analysis
c. Risk
d. Products (of the Company, the Group or third parties).

Investment Committee as ESG Committee

In addition to the above, the Investment Committee is competent to discuss the implementation of the ESG investment strategy through the investment activities planned and performed. In this role, the Investment Committee operates as ESG Committee for the Company.

Remuneration Committee

The Committee supports the Senior Management and the Board in the oversight and implementation of the Remuneration Policy and remuneration practices, with particular reference to the remuneration principles established for the key staff.

The Committee is appointed by the Board of Directors and is made up of three members, of whom two INEDs and one non Board Member, who is also the Chairman.

Control Functions

The Company has established four independent key control functions as per the Solvency II regime and the Corporate Governance Requirements for Insurance Undertakings:

1. Risk Management
2. Compliance
3. Actuarial
4. Internal Audit

Individuals with specific competencies are in charge of these functions within the Company (Risk Management, Compliance, Internal Audit), whereas the Actuarial function is outsourced and entrusted to Ms. Aisling Barrett (Milliman), being the Head of Actuarial Function (PCF 48) following her appointment approval on 11th September 2020, with effective date on 1st October 2020.

Chief Risk Officer ("CRO", PCF 14)

The CRO is responsible for the implementation of the Risk Management System, promoting a culture of risk awareness and reporting throughout the Company and its operations. The CRO is also a member of the Risk & Compliance Committee and Products and Investment Committees, thus ensuring direct reporting and interaction at Committees and Board level on risk related matters.

The main responsibilities of the CRO include:

1. The oversight and implementation of the Company's Risk Management System;
2. Monitoring risks and regularly reporting thereon to the Risk & Compliance Committee and/or the Board, as relevant; and
3. Liaising with all relevant parties (Head of Actuarial Function, General Manager, Chief Financial Officer, Head of Compliance) ensuring, among other things, that the annual Own Risk Solvency Assessment ("ORSA") is prepared and updated as required and submitted to the Board for consideration and, if thought fit, approval.

Head of Compliance – AML Responsibilities (PCF 15)

The Company has appointed a dedicated Head of Compliance with AML Responsibilities (PCF 15). The Head of Compliance reports to the R&CC and to the Board and is responsible for the implementation and oversight of the general compliance plan and compliance strategy of the Company.

The responsibilities of the Head of Compliance include:

1. Monitoring compliance within the Company and its outsourced service providers ("**OSPs**"), making recommendations where required;
2. Reporting on significant instances of non-compliance to the R&C Committee and/or the Board
3. Monitoring any changes affecting compliance and any regulatory changes and informing the Company and/or its OSPs as relevant, where such changes have implications for the Company's processes.
4. Assisting in any correspondence with the CBI and any other Authority.

The R&CC and the Board oversee the risk-based compliance plan and the outcomes thereof.

The Company draws upon external Compliance and Risk support services as needed.

Head of Actuarial Function (PCF 48, Outsourced)

The role of Head of Actuarial Function ("HoAF") is outsourced to a Principal with Milliman.

Head of Internal Audit (PCF 13)

The role of Head of Internal Audit Function has been outsourced until February 2020, as a temporary measure for the transition to insourcing the function, which was completed at the end of February 2020, with the approval of the appointment received from the CBI.

The Internal Audit Function provides an independent and objective service for the auditing of any relevant areas of activity.

B.1.2 Main Changes in Governance Structure

During the year no additional measures have been implemented to enhance the Company's overall governance structures, except for what is reported within the section B.1.1. Head of Internal Audit. The Governance structure is not expected to be affected as a result of the COVID-19 outbreak, with all relevant functions operating efficiently also when working remotely.

B.1.3 Remuneration Policy and Practices

The Company remunerates its people based on the skills and experience, on one hand, and the dedication and results, on the other hand, as well as based more in general on the overall contribution brought to the Company and its business.

For this purpose, it is normally provided that each employee receives a fixed salary and, to a smaller extent, a variable remuneration, depending on the results obtained in areas such as:

1. General conduct;
2. Sense of responsibility and capability to understand and solve problems;
3. Competence shown and work completed, for the overall enhancement of the area of respective expertise ;
4. Interaction with other employees ; and
5. Improvements brought to the Company.

The Company provides a range of benefits to employees, including contractual salary, paid holidays and other variable arrangements for the provision of benefits such as health insurance, accommodation expenses contribution or education-related contributions.

The Company encourages the adherence of employees to supplementary pension or early retirement schemes, for instance accepting, in specific cases, to contribute to any payments into such schemes in a specific proportion and up to a certain amount.

The Company does not follow any policy or practices that could encourage "short termism" or excessive risk taking. For instance, most managers are shareholders of the holding company of the Group (Azimut Holding) and bound by a long term shareholders' agreement, which encourages a process of decision making oriented to long-term as opposed to short-term goals, ensuring more attention is dedicated to sound and prudent management in a long-term perspective. As a consequence, no manager (or employee) in the Company would feel pushed to inflate results or obliged to increase performance every year, even though the Company has effectively experienced significant growth year on year, in terms of both Assets Under Management and revenues, since 2009.

The Remuneration Policy is applied and administered under the supervision and responsibility of the Board of Directors, supported by the Remuneration Committee.

B.1.4 Material Transactions

There were no material transactions with the Shareholder, with persons who exercise a significant influence on the undertaking and / or with members of the administrative, management or supervisory bodies in the Company.

The integration of the Risk Management, Internal Audit and Compliance functions into the organisational structure and the decision making process of the Company is reported within the section B5.

B.2 'Fit and Proper' Requirements

The Company has adopted a Fitness and Probity Policy, which sets out the due diligence checks that must be carried out for any PCF or CF holder or applicant.

For this purpose, any PCF or CF candidate needs to comply with the standards required under the Fitness and Probity Regime introduced with the Central Bank Reform Act of 2010, and any successive integration, modification or implementation.

In particular, any PCF or CF holder or applicant needs to have the necessary skills, experience and qualifications appropriate to their position in accordance with the CBI Guidelines and CBI's guidance on Fitness and Probity Standards of 2014.

Areas that are to be considered for this purpose include:

- Competence and Capability;
- Honesty, Integrity and Reputation;
- Financial Soundness.

This is further implemented through the following:

- Identification;

- Compliance with the minimum competency requirements;
- Professional Qualifications;
- Continuous Professional Development;
- Interview and application;
- References;
- Records of previous experience;
- Concurrent Responsibilities; and
- Individual Questionnaire and candidates' declaration (e.g. engagement letter).

For PCFs, further scrutiny is given to the following aspects:

- Experience, including at Board level;
- Capability to understand the business in all its aspects;
- Capability to see and manage risks for the organization;
- Expertise and expected specific contribution to the Company or its Board (e.g. specific skills in actuarial, legal, commercial or financial matters).

The appointment of a PCF holder is further conditional upon the CBI's approval and, additionally, on a yearly basis all PCF's (and CF) holders are requested to confirm they still meet the fitness and probity requirements. Further, on a yearly basis the PCF holders are subject to specific assessment e.g. through the Board Performance review, which is conducted both on the Board as a collective body and on the individuals.

B.3 RISK MANAGEMENT SYSTEM

The Risk Management System (the "RMS") is underpinned by the core risk management policies according to the requirements of the Solvency II Directive, namely, but not limited to: Risk Management policy, underwriting and reserving, asset-liability management, investment, liquidity and concentration, market abuse, operational, ORSA, reinsurance and other risk mitigation techniques. The policies are reviewed, and revised if necessary, at least on a yearly basis by the Board.

The Company has implemented a Risk Management Policy that defines the guidelines for the Company's approach to Risk Management. The Company has a simplistic operating environment with close collaboration between all stakeholders involved in the activities of the Company. Such a close risk environment enables an early identification of risks, allowing it to address and manage risks in a timely manner.

The CRO is responsible for the implementation of the RMS, promoting a culture of risk awareness and reporting throughout the Company and its operations.

A core element of the RMS is the Board approved Risk Appetite Statement (the "RAS"). The RAS is reviewed no less than annually and is periodically examined in such instances as the regular ORSA Report, also part of the RMS. Together these elements ensure that the Company has a regular and thorough approach to monitoring the status of the Company's risk related matters.

The RMS is integrated into the organisational structure and in the decision making processes of the Company with proper consideration of the persons who effectively run the undertaking or whom hold key functions.

The RMS includes the following:

- strategic decisions set by the Board and policies on risk management;
- definition of the Company's risk appetite and overall risk tolerance limits; and
- identification, measurement, management, monitoring and reporting of risks.

The risk landscape considers the key risk categories according to the Solvency II Directive, those in respect of life assurance and those specific to the Company's risk profile and its business model. The Risk Management Function closely collaborates with the Compliance Function to monitor the legal, regulatory and supervisory environment to determine, together, the identification of any new risks.

The Company's Risk Management Framework (the "RMF") enables the Board and management to understand and appropriately manage and mitigate the risks associated with the Company's objectives over the short, medium and long term, together with the overall level of risk embedded within the function and operational processes and activities of the Company, including those which are the subject of outsourcing arrangements. The CRO is responsible for developing the RMF in terms of Key Risk Indicators (covering financial, underwriting, operational and strategic/business model risks), monitoring and reporting, guidelines, consistently with the Company's risk appetite.

The RMF is intended to reduce, but cannot eliminate the range of possibilities, which might cause detriment to the Company. Similarly, the RMF cannot provide protection with certainty against any failure of the Company to meet its business objectives, or guard against material errors, losses, fraud or breaches of laws and regulations.

Taking all these factors into account, the RMF is intended to provide reasonable assurance that the Company will conduct its business in an orderly and legitimate manner on a continuing basis and that reasonably foreseeable circumstances will not prevent, or limit, the Company from achieving its business objectives.

The Board of Directors is ultimately responsible for ensuring the effectiveness of the risk management system, setting the Company's risk appetite and overall risk tolerance limits as well as approving the main risk management strategies and policies.

The Board should ensure that such strategic decisions and policies are commensurate with the Company's nature, scale and complexity and any specificities as required by its Group. The Board ensures that the specific operations, which are material, and associated risks of the Company are covered and that an integrated, consistent and efficient risk management framework is put in place.

The Board has established a Risk and Compliance Committee that adopts Board approved terms of reference. The primary role of the R&CC, with regard to risk, is to advise the Board on risk appetite and tolerance for future strategy, taking into account the Board's overall risk appetite and the current and foreseeable financial position of the Company. The R&CC oversees the effectiveness of the RMF, which is managed on a day to day basis by the CRO. The R&CC advises the Board on the effectiveness of strategies and policies with respect to maintaining, on an ongoing basis, amounts, types and distribution of both internal capital and own funds adequate to cover the risks of the Company.

The Board sets the overall business strategy of the Company and the CRO sets the Risk Strategy of the Company, as approved by the Board. The Risk Management Function is one of the four key control functions maintained by the Company, it is independent from operations ("first line of defence") and Internal Audit ("third line of defence") and forms an integral part of the Company's "three lines of defence".

The Board of Directors and Risk Management Function promotes a positive and open risk management culture within the Company. Azimut Life employees are encouraged and required to

report and log any operational risk events, breaches, systems and control failures, etc. and to escalate events to their line manager, so that they can be examined and addressed appropriately.

A strong risk culture and risk identification is further embedded within Azimut Life through the following:

- The CRO is a member the R&CC, Products Committee and Investment Committee. This facilitates the CRO to take part in any strategic decision and promptly escalate any potential issue and/or material risks he is aware of;
- The CRO is involved in the material initiatives which may impact on the risk profile of the Company; and
- The CRO works closely with the senior management for the identification and monitoring of the risks faced by the Company.

The RMS is integrated into Board level decision making whereby the CRO, in addition to being a member of the Risk and Compliance Committee, is a regular attendee of Board meetings. Such arrangement ensures that Risk is well represented within the Board and hence decision making level.

B.4 ORSA

The Company maintains a Board approved ORSA Policy that establishes guidelines to enable the Company to issue its ORSA of its current and future risks through a dynamic, forward looking, risk self-assessment process. Stress and scenario testing, approved by the Board of Directors after a thorough discussion, is an integral and important component used in the Company's determination of its own capital needs. Stress and scenario testing sets and evaluates the adequacy of its internal targets and operating capital and liquidity level throughout the business planning cycle.

The ORSA is an integral component of the RMS and it serves as a tool to promote the culture of risk management and to enhance the Company's understanding of the interrelationships between the business strategy, its risk profile and capital and liquidity needs. The ORSA considers all reasonably foreseeable and relevant material risks, is forward-looking and consistent with the Company's business and strategic planning. The ORSA also allows the Company to test its resilience under different scenarios, that are approved by the Board after a thorough discussion.

The ORSA process enables the Company to review its strategy and eventually amend its future business plans due to unforeseen changes in any of the following: underwriting, business mix, pricing of reinsurance, an increase or decrease in investment returns, concentration of risks or return of capital, business mix, to name a few.

The Board, as ultimate owner of the ORSA, set and subsequently challenge the assumptions and the output.

In particular the Board verifies:

- the risk profile of the Company and the key drivers of the risk profile are in line, over the near future, with the approved risk appetite and tolerance limits;
- whether there is sufficient available capital and liquidity to support the current business plan and if the target capital and liquidity requirement are met;
- if there are risks that should be monitored more frequently;
- any material changes to the risk profile over the most recent period;
- risks not covered in the regulatory Solvency Capital, such as, reputational risk and strategic risks, and the significance of these risks;

- key sensitivities in the Company's Balance Sheet, notably its liquidity position, and in the Solvency Capital requirements;
- key drivers of expected profits; and
- the opinion provided by the Head of Actuarial Function to the Board.

In analysing the ORSA results, the BoD could decide upon management action and strategic decisions with the purpose to mitigate risks and ensure that capital requirements and obligations toward policyholders can be met even under unexpectedly adverse circumstances.

The CRO is the responsible for the governance of the processes and procedures in place to conduct the ORSA and will contribute to the ORSA by assessing the risks currently faced by the Company including short and long-term risks. The CRO will ensure the consistency between risk profile, approved risk tolerance limits and the overall solvency needs.

The starting date of ORSA process, which takes place at least annually, is aligned with the business planning cycle. A non-regular ORSA may be triggered by internal or external events, such as, but not limited to: acquisition of another business, a market driven event, significant change in business mix and/or product offering, changes in risk profile or change in capital needs (i.e. an increase in capital).

An ORSA Report is prepared according to the minimum set of contents and requirements prescribed by the ORSA Policy and regulatory guidelines. The Compliance Function submits an ORSA template, after the Board approval of the ORSA report, to the Central Bank of Ireland, accompanied by the Director certification required within the timeframes prescribed.

The Head of Actuarial Function provides an actuarial opinion on the ORSA. The opinion addresses the following areas:

- The range of risks and the adequacy of stress scenarios considered as part of the ORSA process;
- The appropriateness of the financial projections included within the ORSA process; and
- Whether the undertaking is continuously complying with the requirements regarding the calculation of Technical Provisions and potential risks arising from the uncertainties connected to this calculation.

After the ORSA Report is presented and approved by the Board of Directors, the CRO presents the ORSA's key findings to the Company's relevant staff, increasing the awareness of the interconnectedness of operational activities to the overall ORSA Process.

The ORSA Process enables the Company to project and determine future SCR requirements and liquidity needs in order to sufficiently support decision making and a sound RMS.

B.5 Internal Control System

The Company operates an Internal Control System hinging on 3 lines of defence.

In this model, a first level of control lies with the management, with a duty to own and manage activities and controls on the correct conduction of the same (management controls and internal control measures). In this sense, the management have responsibility for directly assessing, controlling and mitigating risk.

A second line of defence is represented by certain control functions, namely Compliance, Risk and Actuarial Function.

A third line of defence is represented by the Internal Audit, which through a risk based approach provides independent review, and therefore reassurance or suggestions for improvement, in relation to the activities and control measures implemented by the other functions, detecting possible weaknesses and reporting directly to the Audit Committee and/or the Board.

B.6 Internal Audit Function

The role of Head of Internal Audit Function has been outsourced until February 2020 to a representative of KPMG, as a temporary measure for the transition to insourcing the function, that took place at the end of February 2020, the approval of the appointment received from the Central Bank of Ireland on 31st December 2019.

Internal Audit activities have been conducted based on an Internal Audit plan approved by the Board every year and its progression has been reported directly to the Audit Committee, at least on a quarterly basis. The Audit Committee oversees therefore the Internal Audit Plan, its implementation and any outcomes thereof.

Internal Audit reports highlight any significant control failings or weaknesses identified, and in the latter case any remedial actions and timings agreed with the management of the Company. In this sense, any findings are shared with the management that must respond to those findings and recommendations. Matters that cannot be resolved through normal channels can be escalated to the Committees and the Board of Directors.

The Internal Audit function has direct access to:

- the day-to-day operations of the business and any functions, staff, documents and service providers of the Company; and
- the Audit Committee and the Board, which approves the Internal Audit Plan and is thereafter competent to hear on any progress thereon

The above described Internal Audit System ensures therefore full independence of the Internal Audit from the management and/or from the day-to-day operations of the business.

B.7 Compliance Function

The Head of Compliance regularly reports to the Risk and Compliance Committee and attends the Board meetings to report on any compliance matter.

Furthermore, the Compliance function:

a) Establishes the controls and monitoring tests required to ensure the compliance with the relevant rules at all times (identification). In case of findings / or omissions that represent a compliance breach, this is recorded in the compliance breach log and reported accordingly in the compliance report for the Risk & Compliance Committee and the Board.
b) Interacts with the staff, the top management and the R&CC. The Compliance (as well as Risk) Function reports directly to the Committees and the Board, independently from the executive

management. The reporting activities take place in accordance with the Compliance Policy and other policies that protect the independence of function.

B.8 Actuarial Function

The function of Head of Actuarial Function ("HoAF") is outsourced to a Principal with Milliman. The Company is also supported by a dedicated actuarial team. The outsourcing of this arrangement adds both professional skills and independent oversight of the Company's Actuarial Function, and the possibility for the Company to obtain the level of resources required by any contingencies and or requirements as they may arise.

Internally, the HoAF is supported by the CRO, in consideration of his actuarial background and of his experience in actuarial and risk matters.

The responsibilities of the HoAF include, but are not limited to, the following:

1. Reviewing and validating the calculation of the technical provisions for the Company, including:
    - ensuring appropriate methodologies, assumptions and models are adopted, discussed and understood by the Board;
    - assessing the quality and adequacy of data used, in particular, without limitation, to assess the consistency of internal and external data used in the calculation of technical provisions against the data quality standards as set in Solvency II;
    - informing the Board and keeping the Board updated on the reliability of calculation and on any changes that may be required; in particular, without limitation, the analysis of the movement in technical provisions, including the comparison of best estimates against experience.
2. Expressing an opinion on the underwriting policy and the adequacy of any reinsurance arrangements;
3. Providing advice and support on the introduction of any new products or amendments of existing products that may materially affect the overall risk profile of the Company and/or its profitability;
4. Providing advice and support to the Company in the Risk Management system, in particular on the ORSA process, including financial consequences of stresses and scenarios and the modelling risk in respect of ORSA and Minimum Capital Requirements ("MCR")/SCR calculations;
5. Providing an opinion to the Board on aspects of the ORSA process.

The Head of Actuarial Function plays an active role within the Company's organisation. On a regular basis, currently monthly, a specific meeting is held when the senior management (usually CEO, CRO and CFO) share with the HoAF any update in relation to the ongoing obligation of the Company with reference to reporting towards the Supervisory Authority, to the Board and the Committees. She is also regularly invited to the Risk Committees and to the Board where actuarial and Solvency II matters are discussed. Apart from the above mentioned regular meetings, whenever the Company is investigating the introduction of new features to the existing products or the launch of new products, an ad-hoc meeting is convened to address any matters arising.

B.9 Outsourcing

The Company has chosen to outsource some of its functions and activities to take advantage of economies of scale and external expertise.

Resorting to outsourcing also allows the Company to have more flexibility in resources to be allocated for the proper discharge of the activities and for the assessment of quality of the service performed, with the possibility of a prompt but controlled replacement where needed, thus relieving the risk of any disruption or discontinuation in certain areas of activity. The Company currently outsources the following activities:

Activity	**Service Provider**	**Jurisdiction of Outsourcee provider**
Actuarial	External	Ireland
Branch AML	Intra-Group	Italy
Fund administration activities	External	Ireland
Policy administration activities	External	Italy
Secretarial Services	External	Ireland
Staff and Payroll	External	Ireland

All the above service providers are based in the EU.

B.10 Adequacy of the System of Governance

Reviews of the corporate governance and the operations of the Board and its Committees continued in 2020. The Company has experienced significant and rapid growth and change in the past years and has undertaken and is committed to continue considering the adequacy of its system of governance on an ongoing basis, to consolidate and ensure at all times a sustainable growth of the business.

C. RISK PROFILE

The Company operates a low-risk business model that is supported by a robust Risk Management Framework that ensures risks are well understood and controlled. This is facilitated by the regular quantification of the risks through the SCR and a culture that promotes the importance of risk management.

The Company's current strategy is to provide life assurance products on a freedom of establishment basis in Italy. The Company's exposure to the most relevant risks are considered in the following sections.

The Company focuses on increasing income by increasing the net assets under management. This is achieved by generating new business whilst reducing lapses. The Company does not aim at taking on any liquidity risk and so maintains appropriate capital assets and actions to cover this, as well as constantly monitoring this risk.

Under normal conditions, the Company has a minimum target on the Solvency II ratio set at 150% of SCR. The Solvency II ratio is calculated on a quarterly basis for regulatory requirements. It is also tested on a number of different scenarios considering the short, medium and long-term time horizon, within the ORSA process, mainly to understand and anticipate the consequences of potential adverse developments in the Company's risk profile.

The Solvency II ratio of the Company is resilient over a number of different scenarios tested within the ORSA over the short, medium and long-term horizon.

The composition of the Company's capital requirement at the end of 2020 is given below, divided by the relevant SCR modules (before the benefit of diversification by SCR risk module is applied).



An overview of the principal risks associated with the business including an outline of how they are each managed is provided below.

C.1 Underwriting Risk

Lapse Risk

The Company defines lapse risk as the risk that a higher (including mass events) than expected rate of lapses reduces the income generated by the Company. The Lapse SCR as of end of 2020 is €123.1 million, before diversification with other underwriting risks.

Lapses are affected by competition, investment returns and policyholders' needs amongst other things.

The Company's products generate positive annual income and hence give rise to an asset (technically a negative provision) on the Solvency II balance sheet in respect of the capitalised value of the projected future profit stream. This suggests that the adverse direction for lapses in the SCR calculation would be an increase. Both the immediate annual income and the capitalised value of projected future income would be reduced by an increase in lapses, especially a mass lapse one. However, a significant portion of the expenses would also be reduced and recoveries would be made also from the tax prepayment. In addition, although the own funds would decrease due to the fall in the capitalised value of future profits, the Company's SCR would also decrease due to the reduction in the amount of the future profit asset at risk. Stresses on increase and decrease of lapses are performed by the Company.

Mortality Risk

The Company defines mortality risk as the risk that the experienced mortality is higher than expected, causing higher cash outflows. The mortality SCR as of the end of 2020 is €4.8 million.

The Company has a limited exposure to mortality risk, as the level of death benefit on top of the units countervalue is relatively low at present and a significant part of the risk is ceded to a primary reinsurer.

Expense Risk

The Company defines expense risk as the risk that unexpected variations in the expenses incurred in servicing insurance contract will materialise. The Expense SCR as of the end of 2020 is €10.3 million.

C.2 Market Risk

The Company defines market risk as the risk arising from potential changes in market rates, prices or liquidity in various markets such as interest rates and spreads, real estate, currency, common shares and commodities. The Market SCR as of the end of 2020, after diversification among market risks, is €88.4 million.

The Company's business is unit-linked without guarantees and, considering the current level of death benefits offered as currently not material, there is no mismatching between assets and liabilities. The assets are invested according to the internal fund's investment policy.

Whilst a fall in AUM would reduce both immediate income and the capitalised value of the projected future income stream, it would also be likely to reduce some of the expenses and the associated SCR, so would not have a significant impact on the Company's solvency position.

C.3 Credit Risk

The Company defines credit risk as the risk that some or all of the monies owed to the Company may remain unpaid or be paid in part and/or with a considerable delay. The Counterparty SCR as of the end of 2020 is €4.3 million. Counterparty risk for the Company is limited to banking relationships, policyholders' exit tax prepayments made to the Italian Tax Authority, reinsurance and management of its own funds. The Company invests the vast majority of such assets in highly liquid instruments and Government bonds. The Company has credit concentration risk, mainly due to its key asset being the prepayment of policyholders' exit tax paid to Italian Tax Authority. The level of concentration is higher at payment date and decreases during the remaining months between payment dates. The exposure with the Reinsurer counterparty, although limited, is protected through additional measures should the Reinsurer financial strength deteriorate. The Company has also implemented specific Risk Appetite metrics in relation to Counterparty risk.

C.4 Liquidity Risk

The Company defines liquidity risk as the risk that the Company will not be able to meet short term financial cash demands as they fall due. Liquidity risk may arise due to illiquidity of the assets held to meet the cash flow requirements (commonly referred to as asset, market, or trading liquidity risk), but also due to insufficient funds being available to meet cash flow requirements (funding liquidity risk).

The Company is exposed to liquidity risk mostly through the requirement to make annual Italian withholding tax prepayments. This risk has significantly eased during the last years since the Company has reached the cap on the Italian withholding tax asset.

Liquidity risk is assessed in the yearly ORSA by projecting the liquid assets in the central scenario and in each of the alternative scenarios tested in order to assess the risk posed to the Company by liquidity exposure. The Company implements a flexible dividend strategy, allowing the reduction of the dividend payments where appropriate. Liquidity is also monitored on a monthly basis and it is managed according to the Company's Liquidity Risk Management policy that sets up both "hard limits" and "soft limits", aimed at anticipating any negative trend related to liquidity.

C.5 Operational Risk

The Solvency II Directive defines 'operational risk' as "the risk of loss arising from inadequate or failed internal processes, personnel or systems, or from external events". The capital requirement for operational risk is therefore calculated using the formula specified in Article 204 of the Delegated Regulations, which for the Company equates to 25% of the amount of expenses incurred during the previous 12 months. The Operational SCR as of the end of 2020 is €19.4 million.

The process through which the Company's operational risk universe is determined and subsequent estimates of frequency and severity are assessed and captured in the Operational Risk Policy. The process safeguards the ongoing improvement of the control environment and ensures that operational risk is identifiable and mitigated as the Company grows. The Company also carries out on a periodical basis a Risk Control and Self Assessment ("RCSA"). The RCSA forms an integral element of the overall operational risk framework, as it provides an excellent opportunity to integrate and co-

ordinate the Company's risk identification and risk management efforts and generally to improve the understanding, control and oversight of its operational risks.

The Company relies on the use of external parties to provide some services, for example policyholder administration and fund administration. The Company is therefore exposed to potential failure of these outsourcing partners. Such arrangements are closely monitored by the Operations, Risk and Compliance Function(s) in accordance with the Outsourcing Policy and with regular reporting to the R&CC on the service level provided by Outsourcees.

The Company has identified cyber risk and business continuity risk as key risk categories where financial loss, disruption or damage to the reputation of the Company from some sort of failure of its information technology systems, or as a result of a major and unexpected event impacting on the capability of the Company to continue its activity without interruptions, might be possible.

The Company is endowed with various systems and levels of protection that significantly mitigate those risks, including cyber attack protection and monitoring, as well as business continuity and disaster recovery plan. The Company regularly performs disaster recovery test and workplace test (i.e. business continuity), aiming at ensuring the continuity of critical Azimut Life's activities.

The Business Continuity plan has been successfully activated in Q1 2020 in light of the Covid-19 emergency. The Board of Directors and the senior management continue to monitor the developments and to liaise with the key outsourcees in order to ensure continuity of essential consumer services.

Further to those levels of protection, the Audit Committee monitors the effectiveness and adequacy of the company's IT systems.

C.6 Other Material Risks

There are many risks that the Company faces in its day to day activities. To identify and keep track of the risks, the CRO maintains a detailed risk register, with periodical reporting to the R&CC on the top risks.

In addition to the key risks identified previously the Company considers the following risk to be important:

Capital Requirement Risk

The Company defines Capital Requirement Risk as the risk that the Company does not have enough capital to cover the regulatory requirements.

The Company has a strong Capital position and the profitability of the Company with the ability to retain the annual profits helps the Company to have adequate capital. All the scenarios tested within the ORSA show the resilience of the Company's Solvency II ratio.

Strategy Business Model Risk

The Company defines Strategy Business Model Risk as the risk that the Company faces should it not be capable of competing effectively.

The Company has a low risk and prudent strategy to minimize the risk that wrong decisions affect the business solidity. Also, Azimut Holding has a long term strategy focused to align the needs of clients and distribution network.

This risk is further mitigated through the Products Committee that is responsible to discuss and analyse characteristics and performances of products, as well as through the management that constantly monitors the Company's and market data to be ready to react to adverse strategic decisions and/or changes in the market and competitive framework.

Reputational Risk

The Company defines Reputational risk as the risk that an event could negatively impact on the reputation of the Company.

The Company is continuously focused on reputational risks that are robustly managed thanks to the different level of controls aimed at minimizing errors that could imply an impact on the reputation.

Governance Risk

The Company defines Governance risk as the risk that insufficient or inadequate governance arrangements could prohibit the compliance of the Company.

The Company monitors the adequacy and effectiveness of the existing governance structure and processes, through constant reporting to the R&CC by the Compliance Function.

Key Person

The Company defines Key Person risk as the risk related to a sudden or unexpected departure of one or more individuals within the Company, holding key roles or exercising key functions and activities.

This risk is mitigated by the fact that no individual holds unfettered powers within the Company and there is a significant interaction between individuals so that back up resources and skills can be put in place whenever required in the event of materialisation of this risk. The Company has also in place a Succession and Contingency Plan that governs the succession of individuals and continuity of functions in Azimut Life.

Emerging Risks

The Company periodically monitors and tracks any new risks (including emerging risks) in the risk register and reports them to the Risk & Compliance Committee and Board of Directors.

The analysis takes into consideration new global trends and identifies new, changing and unforeseen risks that the Company and the insurance industry needs to have on its radar.

The Company has initially assessed (and continues to monitor) the potential impact of Covid-19 across all core risk categories. This is covered under “Significant Events” above.

Among other emerging risks, the Company identified Climate Change Risk. Climate change risk includes all the financial risks stemming from climate change. These risks can materialise in Azimut Life mainly through two channels, physical risk and transition risk. The first refers to risks arising from climate and weather-related events, while the latter includes risks arising from failing to adapt and move toward a lower-carbon economy.

The Company has conducted an analysis to identify potential assets related to climate risk and concluded that the Company's overall exposure to climate related risks can be considered as currently not material.

Further to the impacts potentially arising from the investment activities, climate change risk may also heighten mortality risk, for example as a result of the higher temperatures or other causes such as extreme weather-related events. Considering both the reinsurance strategy of the Company and the relatively low death benefit (as a % of the policy countervalue), the potential mortality risk arising from climate change is not expected to be significant for the Company.

Therefore, considering both the impact on the investment portfolio and mortality exposure, the Company's overall exposure to climate related risks can be considered as currently not material.

C.7 Other Information

Prudent Person Investment

The Company endeavours to pursue adequate investment performance for its clients, and mitigates the risk associated to the investment activity with several techniques, including proper preparation and analysis and adequate diversification, in accordance with the prudent person principle.

The direct use of derivative instruments is permitted only for hedging purposes. They are mainly futures, used with the purpose of hedging the market risk of the internal fund.

Risk Sensitivity

The Company performed a regular ORSA during 2020 taking into account the impact of a series of different stress tests, as approved by the Board, to evaluate the Company's Solvency position and the liquidity level of the Company under certain scenarios.

All stress tests shown Company's resilience both in terms of Solvency II ratio and liquidity needs over the business plan horizon.

D. VALUATION FOR SOLVENCY PURPOSE

The Company has one line of business for the purpose of regulatory reporting: single premium unit-linked whole of life products. A summary balance sheet as at 31 December 2020 is reported below and presented in accordance with regulatory reporting framework.

Amount in €/000	Section	Financial Statements (IFRS)	Solvency II Valuation	QRTs Code
ASSETS				
Deferred acquisition costs		723		R0020
Intangible assets		89		R0030
Property, plant & equipment held for own use	**D.1.1**	1,293	1,293	R0060
Collective Investments Undertakings	**D.1.2**	32,077	32,077	R0180
Holdings in related undertakings, including participations	**D.1.2**	124	124	R0090
Assets held for index-linked and unit-linked contracts	**D.1.4**	5,911,989	6,204,174	R0220
Reins. rec. from Life index-linked and unit-linked	**D.1.5**		(1,764)	R0340
Insurance and intermediaries receivables	**D.1.6**		13,959	R0360
Reinsurance receivable			2,472	R0370
Receivables (trade, not insurance)	**D.1.7**	126,597	133,977	R0380
Cash and cash equivalents	**D.1.8**	340,443	48,258	R0410
Any other assets, not elsewhere shown		31,903	15	R0420
Total assets		**6,445,239**	**6,434,585**	R0500
LIABILITIES				
Technical provisions calculated as a whole	**D.2**		6,178,133	R0700
Best Estimate Liability	**D.2**		(282,811)	R0710
Risk margin	**D.2**		45,239	R0720
Technical provisions - index-linked and unit-linked		6,178,587	6,178,133	R0690
Deferred tax liabilities	**D.3.1**	10	31,009	R0780
Insurance & intermediaries payables	**D.3.2**		42,107	R0820
Reinsurance payables	**D.3.3**		-	R0830
Payables (trade, not insurance)	**D.3.4**	78,307	28,571	R0840
Any other liabilities, not elsewhere shown	**D.3.5**	723		R0880
Total liabilities		**6,257,627**	**6,042,247**	R0900
Excess of assets over liabilities		**187,612**	**392,337**	R1000

D.1 Assets

The valuation methodology of each type of asset within the regulatory balance sheet reported above is described within the respective section.

The Solvency II Balance Sheet does not include the following assets:

- Intangible Assets
- Financial and operating leases
- Deferred Acquisition Costs
- Deferred Insurance Liabilities

D.1.1 Property, plant and equipment

The amount of such assets refers to computer and office equipment used for the purpose of the business and, starting from 2019, with the introduction of IFRS 16 - Leases, this item includes an asset for € 970k which represents the Right of Use of the office building for the duration of the lease.

D.1.2 Collective Investment Undertakings and Holdings in related undertakings, including participations

The Shareholders investments are valued at fair value using the quoted price in active market for the same asset.

D.1.3 Deposit other than cash equivalents

The Deposit other than cash equivalents are recognised at nominal value which is an appropriate approximation of the fair value.

D.1.4 Assets held for index-linked and unit-linked contracts

The value of the unit-linked internal funds related to the contracts issued by the Company is based on the fair value of the underlying financial assets of each of them, net of any payables and receivables the funds may have.

The measurement basis of the assets' fair value has been categorised into a fair value hierarchy as follows:

- Level 1 –Inputs to Level 1 fair values are quoted prices (unadjusted) in active markets for identical assets.
- Level 2 – Inputs to Level 2 fair values are inputs other than quoted prices included within Level 1 that are observable for the asset, either directly or indirectly
- Level 3 – the fair value is derived from valuation technique

Amounts in €/000	**2020**
Level 1	**310,735**
- Government Bonds	36,612
- Open Derivative Positions	-
- Corporate Bonds	-
- Shares	147,524
- ETF/ETC	126,599
Level 2	**5,582,346**
- Mutual Funds	5,207,064
- Corporate Bonds	118,592
- Index Certificate	256,691
Level 3	-
	5,893,081

In order to reconcile the total value of the Unit Linked financial assets amount of € 5,893,081k presented in the table above, to the Assets held for index-linked and unit-linked contracts, the valuation adjustment of € 26.041k and the Internal Funds' payables (€7,133k) should be included.

D.1.5 Reinsurance recoverables from: Life index-linked and unit-linked

The reinsurance recoverable is equal to the expected present value of future cash flows to be paid to and received from the reinsurer, including reinsurance profit share payments.

D.1.6 Insurance and intermediaries receivables

The insurance and intermediaries receivable are non-derivative assets with fixed or determinable payments that are not quoted in an active market, which are held at an amount that is an appropriate approximation of the fair value.

D.1.7 Receivables (trade, not insurance)

These receivables assets are non-derivative assets with fixed or determinable payments that are not quoted in an active market, which are held at an amount that is an appropriate approximation of the fair value. The amount also includes €112,9 million as Italian tax asset prepayment .

D.1.8 Cash and cash equivalents

Cash and cash equivalent include cash deposited with banks and held at call.

D.2 Technical Provision

Technical provisions includes the Best Estimate Liabilities ("BEL") and the Risk Margin. As reported above, Azimut Life has a single material line of business: single premium, unit-linked, whole of life products.

The table below reports the various components.

Amount in €/000	**UL business**
Technical provisions calculated as a whole	6,178,133
Best Estimate Liability	(282,811)
Risk margin	45,239
Technical provisions - index-linked and unit-linked	**5,940,561**

The resulting valuation of the technical provisions under Solvency II represent a realistic estimate of the Company's future obligations with an allowance for some deviation for plausible changes in the estimates, in the form of the risk margin. They are expected to be sufficient to meet the Company's obligations in all scenarios.

The technical provisions under IFRS are split between "Insurance Mathematical provisions" for € 183,070k and "Investment contracts liabilities" for €5,995,517k, while under the Solvency II valuation

the entire amount of €6,178,133k is reported under "Technical provisions calculated as a whole". The Risk Margin of € 45,239k and the (negative) Best Estimate Liability amounting to € -281,821k, are also reported individually under Solvency II, in template S.02.01.

Best Estimate Liability

The BEL is the expected present value, discounted at the risk-free rate, of the probability-weighted average projected future cash-flows.

The calculations have been performed on a best estimate, in accordance with Articles 75 to 86 of the Solvency II Directive. With the exception of a stochastic evaluation of the contribution to the technical provisions from future performance fees, the BEL has been calculated on a deterministic best-estimate basis, with cash flows projected over an 80 year term.

The calculations do not make any allowance for transitional measures, but do take in consideration the specific assumptions made in relation to a board approved management action in relation to a mass lapse scenario.

Risk Margin

The risk margin is the cost of holding some of the components of the SCR over the lifetime of the obligations, with the cost of capital rate set at 6%. The projection of the SCR is the key input to this calculation.

It also represents an addition to BEL to ensure that technical provisions as a whole are equivalent to the amount required by the Company to meet insurance obligations.

The Company does not apply the matching adjustment and volatility adjustment referred to in Article 77b and 77d, respectively, of Directive 2009/138/EC.

The Company does not apply the transitional risk-free interest rate-term structure and transitional deduction referred to Article 308c and 308d, respectively, of Directive 2009/138/EC.

D.3 Other Liabilities

D.3.1 Deferred Tax Liabilities

Deferred taxes are computed in respect of the timing differences arising between the tax base of assets and liabilities and their carrying amounts in the financial statements, applying the tax rates in force in the years in which the aforementioned differences are expected to reverse.

As the BEL is calculated as considering the present value of the future cashflows of the Company, which is assumed to be equal to the future taxable profit, the deduction from the total value of unit funds increases Azimut Life's own funds compared to the statutory accounts basis, which is used to determine corporate tax. This impact is partly offset by the introduction of the risk margin.

The combined impact of these adjustments is € 204.7 million net of reinsurance. A deferred tax liability of €31.0 million is set up on the Solvency II balance sheet in respect of this increase, reflecting the increase in own funds multiplied by the effective corporation tax rate.

D.3.2 Insurance & intermediaries payables

Financial liabilities are initially measured at fair value net of transaction costs. These are subsequently measured at amortised cost using the effective interest method, with interest expense recognised on an effective yield basis, which is equal to the fair value.

D.3.3 Reinsurance payables

The value of these payables has been determined in accordance with the section D.3.2.

D.3.4 Payables (trade, not insurance)

The value of these payables has been determined in accordance with the section D.3.2.

D.3.5 Others

Azimut Life does not have any financial or operating leases as explained in section D.1 and does not have any liabilities for employee benefits. Accordingly, no disclosure has been made.

The deferred income liabilities have not been considered under Solvency II.

D.4 Alternative methods of valuation

Azimut Life does not use any alternative methods for valuation.

D.5 Any other information

This report has been prepared on a going concern basis. In assessing whether the going concern assessment is appropriate, the Directors have considered all information available and have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future.

In making this assessment the directors considered the following key factors:

a) the Company's capital position and the surplus over its required solvency capital ratio and minimum capital ratio;

b) the potential range of impact that Covid-19 may have on this surplus taking account of the Company's ORSA stress testing where appropriate;

c) the Company's initial assessment of the impact on its business, claims and investments;

d) the level of re-insurance;

e) the credit rating of Company's re-insurance counterparties; and

f) the Company's liquidity position.

The Directors have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from the date of this report. The Directors are satisfied with the Company's performance during the year and consider that it is well placed to continue its development in the future. The Directors have an active role in the development of the Company through the ongoing review and oversight of budgets and performance. For these reasons, the Directors consider it appropriate that these accounts were prepared on a going concern basis.

As a result of the net profit earned during 2020 and given the expected positive cash flow, the Company intends to pay a dividend to its shareholder in mid 2021. The dividend proposed amounts to € 55.9 Million. This will reduce the Own Funds from €392,337k to €336,437k.

There is no additional material information regarding the valuation of assets and liabilities for solvency purposes.

E. CAPITAL MANAGEMENT

E.1 Own Funds

E.1.1 Objectives, policies and processes employed for managing own funds

The Company has a single shareholder, Azimut Holding SpA, and the called up capital is fully paid up. Azimut Life has no debt financing, nor does it have any plans to raise debt or issue new shares in the short or medium term.

The Company's own funds are primarily invested in bank accounts and a mutual fund investing in cash deposits. There is no intention to change the disposition of own fund items.

A Board approved Capital Management policy is adopted, whereby a provision to maintain a minimum level of Own Funds equal to 150 % of the SCR has been included.

In addition, a minimum buffer of cash amount, set up within the Liquidity Risk Management Policy, should be kept at all times to face any potential liquidity shortfall. No capital is planned to be issued in the short or medium term.

On an annual basis, and having regarded to the results of stress tests applied to projections over the planning period included within the ORSA process, the Board will consider whether a dividend should be paid to remit any surplus of the capital over the level of mentioned above, having taken into consideration the liquidity needs. This was the case this year as per note D.5 above.

E.1.2 Analysis and details of own funds items

The table below reports the information in relation to the structure, amount and quality of own funds as of 31 December 2020, compared to the same structure of the previous year. It also includes the eligible amount of own funds to cover SCR and MCR classified by tier.

Amount in €/000	**2020**	**2019**
Tier 1 unrestricted at beginning of the year		
Ordinary share capital (gross of own shares)	650	650
Other own fund items approved by the supervisory authority as basic own funds not specified above	9,350	9,350
Reconciliation reserve	289,142	253,818
Total Own Funds to cover SCR and MCR	**299,142**	**263,818**
Tier 1 unrestricted at the end of the year		
Ordinary share capital (gross of own shares)	650	650
Other own fund items approved by the supervisory authority as basic own funds not specified above	9,350	9,350
Reconciliation reserve	326,437	289,142
Total Own Funds to cover SCR and MCR	**336,437**	**299,142**
SCR	168,878	145,220

Ratio SCR	**199%**	**206%**
MCR	42,219	40,998
Ratio MCR	**797%**	**730%**

Reconciliation Reserve:		
Excess of assets over liabilities	392,337	323,842
Foreseeable Dividends	55,900	24,700
Other basic own funds items	10,000	10,000
Reconciliation Reserve	**326,437**	**289,142**

The additional item classified as Tier 1 unrestricted for the amount of €9,350k relates to the amount of all the capital contributions, for which the approval of such classification has been received from the CBI.

The reconciliation reserve represents retained profits and the difference between technical provisions for solvency purposes and the liabilities to customers under investment and insurance contracts reported in the financial statements.

The Company intends to pay a dividend to its shareholder in 2021, in relation to its 2020 year end. The dividend proposed amounts to € 55.9 Million. This will reduce the Own Funds from € 392,337k to € 336,437k.

E.1.3 Material differences between equity as shown in Azimut Life's financial statements and the excess of assets over liabilities as calculated for solvency purposes

The difference between the Company's equity as reported within the audited financial statements and the Solvency II own funds above is due to the BEL impact, risk margin, reinsurance asset and Solvency II deferred tax adjustment (see section D for further information on these items).

E.1.4 Basic own funds subject to transitional arrangements

No own funds of the Company are subject to transitional arrangements

E.1.5 Ancillary own funds

No ancillary own funds are included within the own funds amount.

E.1.6 Items deducted from own funds

No deductions have been applied to own funds and there are no significant restrictions affecting their availability and transferability.

E.1.7 Own funds

Azimut Life does not have additional ratios to the ones included in template S.23.01.

E.2 Solvency Capital Requirement and Minimum Capital Requirement

E.2.1 SCR and MCR – Comparison with previous year end

Amount in €/000	2020	2019
Capital Requirement		
SCR	168,878	145,220
MCR	42,219	40,998

E.2.2 SCR Split by risk module

Azimut Life's components of the SCR, calculated using the Standard Formula, are detailed within the table below and compared to last year figures.

Amount in €/000	2020	2019
Market Risk	88,435	66,296
Counterparty Default Risk	4,255	4,804
Life Risk	128,912	111,502
Diversification	(46,617)	(37,778)
Basic Solvency Capital Requirement	**174,985**	**144,825**
Calculation of Solvency Capital Requirement		
Operational Risk	19,351	22,287
Loss-absorbing capacity of deferred taxes	(25,458)	(21,892)
Solvency Capital Requirement	**168,878**	**145,220**

E.2.3 Standard Formula Simplification

The Company is not using any Standard Formula simplifications.

E.2.4 Specific parameters of the Standard Formula

The Company is not using any undertaking specific parameters.

E.2.5 Capital Add-ons

Azimut Life does not have any capital add-ons or specific parameters applied to the SCR calculation.

E.2.6 MCR Input

The combined MCR is calculated as:

- The higher amount between the Linear MCR and the MCR Floor (25% of the SCR)
- The lower amount between the Linear MCR and the MCR Cap (45% of the SCR)

Azimut Life's Linear MCR at 31 December 2020 amounts to € 41,486k, which is lower than the MCR Floor of € 42,219k, therefore the MCR Floor applies for the Combined MCR.

E.3 Use of the duration-based equity risk sub-module in the calculation of the Solvency Capital Requirement

Azimut Life does not use the duration-based equity risk sub-module in the calculation of its SCR.

E.4 Internal Model Information

Azimut Life is using the standard formula to calculate the Solvency Capital Requirement, so internal model is not used.

E.5 Non-compliance with the Minimum Capital Requirement and non-compliance with the Solvency Capital Requirement

Azimut Life's capital exceeds both the MCR and the SCR throughout the reporting period.

E.6 Loss Absorbing Capacity of Deferred Taxes ("LACDT")

The Company implemented a deferred tax policy under the risk management system, describing the Company's approach in relation to LACDT.

As the Company does not have any adjustment for the loss-absorbing capacity of technical provisions, the LACDT adjustment is determined by multiplying the effective corporation tax rate to the BSCR plus the Operational risk SCR.

As at 31 December 2020, the LACDT are lower than the DTL: under this scenario, the Company can support the LACDT with the tax liability that sits on the opening balance sheet, on the basis that if the SCR loss were to occur, then future tax payments are expected to be reduced.

The SCR has been overall adjusted by €25.5 million for the LACDT.

E.7 Any other information

There is no additional information in relation to the capital management of the Company

APPENDIX 1 – REPORTING TEMPLATES

The table below reports the quantitative reporting templates (QRTs) to be included within the SFCR.

QRT Code	QRT Name	Reported / Not Reported
S.02.01.02	Balance sheet	Reported
S.12.01.02	Life and Health SLT Technical Provisions	Reported
S.23.01.01	Own funds	Reported
S.25.01.21	Solvency Capital Requirement - for undertakings on Standard Formula	Reported
S.28.01.01	Minimum Capital Requirement - Only life or only non-life insurance or reinsurance activity	Reported

(Amounts in €'000)

S.02.01.02

Balance sheet

		Solvency II value
	Assets	C0010
R0030	Intangible assets	
R0040	Deferred tax assets	
R0050	Pension benefit surplus	
R0060	Property, plant & equipment held for own use	1,293
R0070	Investments (other than assets held for index-linked and unit-linked contracts)	32,201
R0080	*Property (other than for own use)*	
R0090	*Holdings in related undertakings, including participations*	124
R0100	*Equities*	
R0110	*Equities - listed*	
R0120	*Equities - unlisted*	
R0130	*Bonds*	
R0140	*Government Bonds*	
R0150	*Corporate Bonds*	
R0160	*Structured notes*	
R0170	*Collateralised securities*	
R0180	*Collective Investments Undertakings*	32,077
R0190	*Derivatives*	
R0200	*Deposits other than cash equivalents*	
R0210	*Other investments*	
R0220	Assets held for index-linked and unit-linked contracts	6,204,174
R0230	Loans and mortgages	
R0240	*Loans on policies*	
R0250	*Loans and mortgages to individuals*	
R0260	*Other loans and mortgages*	
R0270	Reinsurance recoverables from:	-1,764
R0280	*Non-life and health similar to non-life*	
R0290	*Non-life excluding health*	
R0300	*Health similar to non-life*	
R0310	*Life and health similar to life, excluding index-linked and unit-linked*	
R0320	*Health similar to life*	
R0330	*Life excluding health and index-linked and unit-linked*	
R0340	*Life index-linked and unit-linked*	-1,764
R0350	Deposits to cedants	
R0360	Insurance and intermediaries receivables	13,959
R0370	Reinsurance receivables	2,472
R0380	Receivables (trade, not insurance)	133,977
R0390	Own shares (held directly)	
R0400	Amounts due in respect of own fund items or initial fund called up but not yet paid in	
R0410	Cash and cash equivalents	48,258
R0420	Any other assets, not elsewhere shown	15
R0500	**Total assets**	6,434,585

		Solvency II value
	Liabilities	C0010
R0510	Technical provisions - non-life	
R0520	*Technical provisions - non-life (excluding health)*	
R0530	*TP calculated as a whole*	
R0540	*Best Estimate*	
R0550	*Risk margin*	
R0560	*Technical provisions - health (similar to non-life)*	
R0570	*TP calculated as a whole*	
R0580	*Best Estimate*	
R0590	*Risk margin*	
R0600	Technical provisions - life (excluding index-linked and unit-linked)	
R0610	*Technical provisions - health (similar to life)*	
R0620	*TP calculated as a whole*	
R0630	*Best Estimate*	
R0640	*Risk margin*	
R0650	*Technical provisions - life (excluding health and index-linked and unit-linked)*	
R0660	*TP calculated as a whole*	
R0670	*Best Estimate*	
R0680	*Risk margin*	
R0690	Technical provisions - index-linked and unit-linked	5,940,561
R0700	*TP calculated as a whole*	6,178,133
R0710	*Best Estimate*	-282,811
R0720	*Risk margin*	45,239
R0740	Contingent liabilities	
R0750	Provisions other than technical provisions	
R0760	Pension benefit obligations	
R0770	Deposits from reinsurers	
R0780	Deferred tax liabilities	31,009
R0790	Derivatives	
R0800	Debts owed to credit institutions	
R0810	Financial liabilities other than debts owed to credit institutions	
R0820	Insurance & intermediaries payables	42,107
R0830	Reinsurance payables	
R0840	Payables (trade, not insurance)	28,571
R0850	Subordinated liabilities	
R0860	*Subordinated liabilities not in BOF*	
R0870	*Subordinated liabilities in BOF*	
R0880	Any other liabilities, not elsewhere shown	
R0900	**Total liabilities**	6,042,247
R1000	**Excess of assets over liabilities**	392,337

QRTs: S.12.01.02 – Life and Health SLT Technical Provisions

		Insurance with profit participation	Index-linked and unit-linked insurance			Other life insurance			Annuities stemming from non-life insurance contracts and relating to insurance obligation other than health insurance obligations	Accepted reinsurance					**Total (Life other than health insurance, including Unit-Linked)**	Health insurance (direct business)			Annuities stemming from non-life insurance contracts and relating to health insurance obligations	Health reinsurance (reinsurance accepted)	**Total (Health similar to life insurance)**
				Contracts without options and guarantees	Contracts with options or guarantees		Contracts without options and guarantees	Contracts with options or guarantees			Insurance with profit participation	Index-linked and unit-linked insurance	Other life insurance	Annuities from non-life insurance contracts relating to ins. obligation other than health ins. obligations			Contracts without options and guarantees	Contracts with options or guarantees			
		C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0110	C0120	C0130	C0140	C0150	C0160	C0170	C0180	C0190	C0200	C0210
Technical provisions calculated as a whole	**R0010**		6,178,133												6,178,133						
Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default associated to TP calculated as a whole	**R0020**																				
Technical provisions calculated as a sum of BE and RM																					

Best Estimate																					
Gross Best Estimate	**R0030**			-282,811											-282,811						
Total recoverables from reinsurance/SPV and Finite Re before the adjustment for expected losses due to counterparty default	**R0040**			-1,764											-1,764						
Recoverables from reinsurance (except SPV and Finite Re) before adjustment for expected losses	**R0050**			-1,764											-1,764						
Recoverables from SPV before adjustment for expected losses	**R0060**																				
Recoverables from Finite Re before adjustment for expected losses	**R0070**																				
Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default	**R0080**			-1,764											-1,764						
Best estimate minus recoverables from reinsurance/SPV and Finite Re	**R0090**			-281,047											-281,047						
Risk Margin	**R0100**		45,239												45,239						
Amount of the transitional on Technical Provisions																					
Technical Provisions calculated as a whole	**R0110**																				
Best estimate	**R0120**																				
Risk margin	**R0130**																				
Technical provisions - total	**R0200**		5,940,561												5,940,561						

QRTs: S.23.01.01 – Own Funds

		Total	Tier 1 - unrestricted	Tier 1 - restricted	Tier 2	Tier 3
		C0010	C0020	C0030	C0040	C0050
Basic own funds before deduction for participations in other financial sector as foreseen in article 68 of Delegated Regulation 2015/35						
Ordinary share capital (gross of own shares)	**R0010**	650	650		0	
Share premium account related to ordinary share capital	**R0030**	0	0		0	
Initial funds, members' contributions or the equivalent basic own - fund item for mutual and mutual-type undertakings	**R0040**	0	0		0	
Subordinated mutual member accounts	**R0050**	0		0	0	0
Surplus funds	**R0070**	0	0			
Preference shares	**R0090**	0		0	0	0
Share premium account related to preference shares	**R0110**	0		0	0	0
Reconciliation reserve	**R0130**	326,437	326,437			
Subordinated liabilities	**R0140**	0		0	0	0
An amount equal to the value of net deferred tax assets	**R0160**	0				0
Other items approved by supervisory authority as basic own funds not specified above	**R0180**	9,350	9,350	0	0	0
Own funds from the financial statements that should not be represented by the reconciliation reserve and do not meet the criteria to be classified as Solvency II own funds						
Own funds from the financial statements that should not be represented by the reconciliation reserve and do not meet the criteria to be classified as Solvency II own funds	**R0220**	0				
Deductions						
Deductions for participations in financial and credit institutions	**R0230**	0	0	0	0	
Total basic own funds after deductions	**R0290**	336,437	336,437	0	0	0
Ancillary own funds						
Unpaid and uncalled ordinary share capital callable on demand	**R0300**	0			0	
Unpaid and uncalled initial funds, members' contributions or the equivalent basic own fund item for mutual and mutual - type undertakings, callable on demand	**R0310**	0			0	
Unpaid and uncalled preference shares callable on demand	**R0320**	0			0	0
A legally binding commitment to subscribe and pay for subordinated liabilities on demand	**R0330**	0			0	0
Letters of credit and guarantees under Article 96(2) of the Directive 2009/138/EC	**R0340**	0			0	
Letters of credit and guarantees other than under Article 96(2) of the Directive 2009/138/EC	**R0350**	0			0	0

Supplementary members calls under first subparagraph of Article 96(3) of the Directive 2009/138/EC	R0360	0			0	
Supplementary members calls - other than under first subparagraph of Article 96(3) of the Directive 2009/138/EC	R0370	0			0	0
Other ancillary own funds	R0390	0			0	0
		0	0			

		Total	Tier 1 - unrestricted	Tier 1 - restricted	Tier 2	Tier 3
		C0010	C0020	C0030	C0040	C0050
Total ancillary own funds	R0400	0			0	0
Available and eligible own funds						
Total available own funds to meet the SCR	R0500	336,437	336,437	0	0	0
Total available own funds to meet the MCR	R0510	336,437	336,437	0	0	
Total eligible own funds to meet the SCR	R0540	336,437	336,437	0	0	0
Total eligible own funds to meet the MCR	R0550	336,437	336,437	0	0	
SCR	R0580	168,878				
MCR	R0600	42,219				
Ratio of Eligible own funds to SCR	R0620	199,22%				
Ratio of Eligible own funds to MCR	R0640	796.88%				

		Total	
		C0060	
Reconciliation reserve			
Excess of assets over liabilities	R0700	392,337	
Own shares (held directly and indirectly)	R0710	0	
Foreseeable dividends, distributions and charges	R0720	55,900	
Other basic own fund items	R0730	10,000	
Adjustment for restricted own fund items in respect of matching adjustment portfolios and ring fenced funds	R0740	0	
Reconciliation reserve	R0760	326,437	
Expected profits			
Expected profits included in future premiums (EPIFP) - Life business	R0770	0	
Expected profits included in future premiums (EPIFP) - Non- life business	R0780	0	
Total Expected profits included in future premiums (EPIFP)	R0790	0	

QRTs: S.25.01.21 – Solvency Capital Requirement - for undertakings on Standard Formula

		Net solvency capital requirement	Gross solvency capital requirement	Allocation from adjustments due to RFF and Matching adjustments portfolios
		C0030	C0040	C0050
Market risk	R0010	88,435	88,435	0
Counterparty default risk	R0020	4,255	4,255	0
Life underwriting risk	R0030	128,912	128,912	0
Health underwriting risk	R0040	0	0	0
Non-life underwriting risk	R0050	0	0	0
Diversification	R0060	-46,617	-46,617	
Intangible asset risk	R0070	0	0	
Basic Solvency Capital Requirement	R0100	174,985	174,985	

Calculation of Solvency Capital Requirement		C0100
Adjustment due to RFF/MAP nSCR aggregation	R0120	0
Operational risk	R0130	19,351
Loss-absorbing capacity of technical provisions	R0140	0
Loss-absorbing capacity of deferred taxes	R0150	-25,458
Capital requirement for business operated in accordance with Art. 4 of Directive 2003/41/EC	R0160	0
Solvency Capital Requirement excluding capital add-on	R0200	168,878
Capital add-on already set	R0210	0
Solvency capital requirement for undertakings under consolidated method	R0220	168,878
Other information on SCR		
Capital requirement for duration-based equity risk sub-module	R0400	0
Total amount of Notional Solvency Capital Requirements for remaining part	R0410	0
Total amount of Notional Solvency Capital Requirements for ring fenced funds	R0420	0
Total amount of Notional Solvency Capital Requirements for matching adjustment portfolios	R0430	0
Diversification effects due to RFF nSCR aggregation for article 304	R0440	0
Method used to calculate the adjustment due to RFF/MAP nSCR aggregation	R0450	4 - No adjustment
Net future discretionary benefits	R0460	0

QRTs: S.28.01.01 – Minimum Capital Requirement - Only life or only non-life insurance or reinsurance activity

		Net (of reinsurance/SPV) best estimate and TP calculated as a whole	Net (of reinsurance) written premiums in the last 12 months
		C0020	C0030
Medical expense insurance and proportional reinsurance	R0020	0.0	0.0
Income protection insurance and proportional reinsurance	R0030	0.0	0.0
Workers' compensation insurance and proportional reinsurance	R0040	0.0	0.0
Motor vehicle liability insurance and proportional reinsurance	R0050	0.0	0.0
Other motor insurance and proportional reinsurance	R0060	0.0	0.0
Marine, aviation and transport insurance and proportional reinsurance	R0070	0.0	0.0
Fire and other damage to property insurance and proportional reinsurance	R0080	0.0	0.0
General liability insurance and proportional reinsurance	R0090	0.0	0.0
Credit and suretyship insurance and proportional reinsurance	R0100	0.0	0.0
Legal expenses insurance and proportional reinsurance	R0110	0.0	0.0
Assistance and proportional reinsurance	R0120	0.0	0.0
Miscellaneous financial loss insurance and proportional reinsurance	R0130	0.0	0.0
Non-proportional health reinsurance	R0140	0.0	0.0
Non-proportional casualty reinsurance	R0150	0.0	0.0
Non-proportional marine, aviation and transport reinsurance	R0160	0.0	0.0
Non-proportional property reinsurance	R0170	0.0	0.0

Linear formula component for life insurance and reinsurance obligations

		C0040
MCRL Result	R0200	41,486

		Net (of reinsurance/SPV) best estimate and TP calculated as a whole	Net (of reinsurance/SPV) total capital at risk
		C0050	C0060
Obligations with profit participation - guaranteed benefits	R0210	0.0	
Obligations with profit participation - future discretionary benefits	R0220	0.0	
Index-linked and unit-linked insurance obligations	R0230	5,897,115	
Other life (re)insurance and health (re)insurance obligations	R0240		
Total capital at risk for all life (re)insurance obligations	R0250		294,036

Overall MCR calculation

		C0070
Linear MCR	R0300	41,486
SCR	R0310	168,878
MCR cap	R0320	75,995
MCR floor	R0330	42,219
Combined MCR	R0340	42,219
Absolute floor of the MCR	R0350	3,700
		C0070
Minimum Capital Requirement	R0400	42,219